Novo Nordisk CEO Faces US Senate Hearing Over Ozempic Pricing Controversy
24.09.2024, 18:00
In a tense Senate hearing, Novo Nordisk's CEO defended the high prices of popular weight-loss drugs Ozempic and Wegovy, stating that the company is not solely to blame for costs, pointing fingers at pharmacy benefit managers. U.S. Senator Bernie Sanders criticized these high prices, expressing...